Identiv, Inc. announced that on October 17, 2022, Robin R. Braun and Nina B. Shapiro resigned from the board of directors, including all committees thereof, effective immediately. On October 18, 2022, the Board appointed Laura Angelini and Richard E. Kuntz, M.D., M.Sc. to serve as members of the Board.

In connection with their appointment to the Board, each of Ms. Angelini and Dr. Kuntz will enter into the Company's standard form of indemnification agreement. Laura Angelini, age 58, most recently served as General Manager of the Global Business Unit at Baxter International Inc. from October 2016 to July 2021. Prior to that, Ms. Angelini served in various roles at Johnson & Johnson from July 1991 to September 2016, including as President of North America and Global Franchise Development from 2013 to 2016, Vice-President of Global Strategic Marketing of Ethicon from 2012 to 2013, and Vice President of Medical Devices & Diagnostics of Eastern Europe from 2010 to 2011.

Ms. Angelini currently serves as a member of the board of directors of DCC plc and as a member of the board of trustees of Jacksonville University. Ms. Angelini received a bachelor's degree from University La Sapienza, Rome Italy. Richard E. Kuntz, age 65, most recently served as Senior Vice President, Chief Medical and Scientific Officer of Medtronic plc (NYSE: MDT), a medical device company, from January 2015 to May 2022, and of Medtronic, Inc. from August 2009 to December 2014.

Prior to that, he was Senior Vice President and President of Medtronic Neuromodulation from October 2005 to August 2009. Prior to his 17 years at Medtronic, Dr. Kuntz was the Founder and Chief Scientific Officer of the Harvard Clinical Research Institute and he also served as Associate Professor of Medicine at Harvard Medical School, Chief of the Division of Clinical Biometrics, and an interventional cardiologist in the division of cardiovascular diseases at the Brigham and Women's Hospital in Boston. Dr. Kuntz also currently serves as a member of the board of directors of ZimVie Inc., a medical technology company, and Rockley Photonics Holdings Limited, a digital health monitoring systems company.

Dr. Kuntz graduated from Miami University and received his medical degree from Case Western Reserve University School of Medicine. He completed his residency and chief residency in internal medicine at the University of Texas Southwestern Medical School, and then completed fellowships in cardiovascular diseases and interventional cardiology at the Beth Israel Hospital and Harvard Medical School, Boston. Dr. Kuntz received his Master of Science in biostatistics from the Harvard T.H. Chan School of Public Health.